Tillotts Pharma UK

We focus on gastroenterology

COVID-19

Tillotts Pharma UK are here to support, especially in these unprecedented times.

We would like to assure you that stock levels of our medicines will be maintained and should continue to be taken as prescribed unless advised differently by a healthcare professional.

We have stopped all promotional face-to-face contact from our sales teams at this time, but you may see some of them in both clinical and non-clinical voluntary positions supporting the NHS.

We would like to take this opportunity to show our gratitude to the NHS and wish everyone well.

If you have any queries please contact us on: 01522 813500 or UKinfo@tillotts.com

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more information on the safety of these medicines.

Tillotts in the UK

Tillotts Pharma AG has a strong presence in Europe with affiliates and distributors in all major European markets. The UK business is the largest wholly owned affiliate of Switzerland based Tillotts Pharma AG, and part of the Japanese Zeria Group.

Tillotts Pharma UK Ltd was established in March 2010. Jeremy Thorpe (Managing Director) joined in July 2012, with a clear focus on optimising the portfolio of gastrointestinal (GI) health products. Tillotts Pharma UK is now a market leader.

Learn more about us » See our video »

GI health

Improving care for people with GI diseases

Since its foundation, Tillotts has been committed to improving care for people with gastrointestinal (GI) diseases. We collaborate with healthcare professionals and GI-experts to develop and market medicines for the treatment of diseases of the digestive system.

Our specific focus on the digestive system means we have in-depth knowledge of the challenges that gastroenterologists and hepatologists face on a daily basis. It also helps us look for innovative ways to improve care and quality of life for the 5–6 million people who live with inflammatory bowel diseases worldwide.

Inflammatory Bowel Disease (IBD)
IBD is a group of chronic conditions in which the body’s immune system attacks part of the digestive system. These condi [...]
Read more »

Ulcerative Colitis (UC)
Ulcerative colitis involves chronic inflammation of the lining of the large intestine. Unlike Crohn’s disease, which can [...]
Read more »

Crohn’s Disease (CD)
Crohn’s disease is caused by chronic inflammation of the digestive tract. Symptoms vary, but often include abdominal pai [...]
Read more »

Microscopic Colitis (MC)
Like ulcerative colitis (UC), microscopic colitis affects the colon and rectum, however the inflammation of the intestin [...]
Read more »

Why Tillotts

At Tillotts Pharma UK, we are a dedicated and passionate group of people. Everything we do is guided by how we can improve the lives of people with GI diseases, and support those who care for them.
We prioritise hiring the right people. The success of the business comes from the relationships we’ve built with our customers, and to do this we need good people.

Explore our current opportunities

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Tillotts Pharma UK Ltd on 01522 813500 or uksafety@tillotts.com

Close window

You are about to leave tillotts.co.uk for an external website. Tillotts is not responsible for the content of other websites.

Go back

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Tillotts Pharma UK Ltd on 01522 813500 or uksafety@tillotts.com

Close window

We use cookies on this website. By continuing to use our services, you are giving us your consent to use cookies.